| July 24, 2014
Results hurt by patent expirations: Eli Lilly CEO
John Lechleiter, Eli Lilly CEO, breaks down the pharmaceutical giant's quarterly results. And Lechleiter weighs in on the benefits of investing in R&D.
Sorry, we do not have a transcript available for this video at this time.